Catalog No.
DVV00307
Expression system
Mammalian Cells
Species reactivity
SARS-CoV-2 (2019-nCoV), Omicron, BA.4/5 strain, BA.5 strain, BA.4 strain
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2
Concentration
3.03 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P0DTC2
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
VIR-7831, GSK4182136, S309, CAS: 2423014-07-5
Clone ID
Sotrovimab
Sotrovimab, PMID: 34165945
An EUA for sotrovimab for treatment of COVID-19, PMID: 34181630
COVID antibody treatments show promise for preventing severe disease, PMID: 33712752
Effects of the glycosylation of the receptor binding domain (RBD dimer)-based Covid-19 vaccine (ZF2001) on its humoral immunogenicity and immunoreactivity. [DVV00307]
Monitoring the emergence of resistance with sotrovimab in immunocompromised patients with COVID-19: LUNAR study., PMID:40398499
An integrated multiscale computational framework deciphers SARS-CoV-2 resistance to sotrovimab., PMID:40394898
Case Report: Persistent COVID-19 in a fully vaccinated Japanese man being treated with rituximab and epcoritamab for diffuse large B-cell lymphoma., PMID:40370717
Comparative Analysis of Early COVID-19 Treatment Efficacy in a Multicentric Regional Cohort in Italy: Emulation of a Series of Target Trials., PMID:40326978
Antiviral prescription of mild to moderate COVID-19 and adherence to official recommendations in Spanish emergency departments., PMID:40320950
Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients., PMID:40279347
Clinical and molecular landscape of prolonged SARS-CoV-2 infection with resistance to remdesivir in immunocompromised patients., PMID:40160532
Pharmacokinetics and Safety of Single-Dose Sotrovimab in High-Risk Children and Adolescents With Mild-to-Moderate COVID-19., PMID:40146813
Comparative Analysis of Neuropsychiatric Adverse Reactions Associated with Remdesivir and Nirmatrelvir/Ritonavir in COVID-19 Treatment: Insights from EudraVigilance Data., PMID:40142695
Efficacy and Safety of Sotrovimab Versus Oral Antiviral for Early Treatment in High-Risk Patients in Omicron Era: A Multicenter Retrospective Study., PMID:40137701
Impact of treatment of COVID-19 with sotrovimab on post-acute sequelae of COVID-19 (PASC): an analysis of National COVID Cohort Collaborative (N3C) data., PMID:40120069
Effectiveness of pharmacological treatments for COVID-19 due to SARS-CoV-2: a systematic literature review., PMID:40093322
Impact of SARS-CoV-2 variant mutations on susceptibility to monoclonal antibodies and antiviral drugs: a non-systematic review, April 2022 to October 2024., PMID:40084420
SARS-CoV-2 genomic evolution during a severe and long-lasting omicron infection under antiviral therapy., PMID:40082784
Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeutics., PMID:40056806
Monoclonal Antibodies in Prevention and Early Treatment of COVID-19 in Lung Transplant Recipients: A Systematic Review and Perspective on the Role of Monoclonal Antibodies in the Future., PMID:39995815
Real-World Effectiveness of Sotrovimab in Patients Infected With SARS-CoV-2 Omicron Subvariant BA.2 in Western Sydney, Australia., PMID:39945377
Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial., PMID:39922466
Real-World Effectiveness of Sotrovimab in Ambulatory Patients With COVID-19: A Retrospective Cohort Study Using a Large Administrative Claims Database in the United States., PMID:39909767
Safety and tolerability of intramuscular sotrovimab administered at different injection sites: results from the Phase 1 COSMIC study., PMID:39881564
The evolving landscape of COVID-19: factors associated with in-hospital COVID-19 related mortality during the 2023-2024 phase of JN.1 subvariant dominance., PMID:39871210
Fc-binding nanodisc restores antiviral efficacy of antibodies with reduced neutralizing effects against evolving SARS-CoV-2 variants., PMID:39856746
Uptake and safety of Sotrovimab for prevention of severe COVID-19 in a cohort and self-controlled case series study., PMID:39820075
Comparative Effectiveness of Outpatient COVID-19 Therapies in Solid Organ Transplant Recipients., PMID:39791933
Affinity maturation endows potent activity onto class 6 SARS-CoV-2 broadly neutralizing antibodies., PMID:39746041
Comparative Effectiveness of Antivirals and Monoclonal Antibodies for Treating COVID-19 Patients Infected With Omicron Variant: A Systematic Review and Network Meta-Analysis., PMID:39722466
Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites., PMID:39668507
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study., PMID:39661366
Therapeutic Potential of Neutralizing Monoclonal Antibodies (nMAbs) against SARS-CoV-2 Omicron Variant., PMID:39543801
Characterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infection., PMID:39405332
Comparison of the Neutralization Power of Sotrovimab Against SARS-CoV-2 Variants: Development of a Rapid Computational Method., PMID:39388246
Real-world effectiveness of early anti-SARS therapy in severely immunocompromised COVID-19 outpatients during the SARS-CoV-2 omicron variant era: a propensity score-adjusted retrospective cohort study., PMID:39374379
Does early combination vs. Monotherapy improve clinical outcomes of clinically extremely vulnerable patients with COVID-19? Results from a retrospective propensity-weighted analysis., PMID:39367485
Adverse events associated with SARS-CoV-2 neutralizing monoclonal antibodies using the FDA adverse event reporting system database., PMID:39345748
Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves., PMID:39343244
Identification of antibody-resistant SARS-CoV-2 mutants via N4-Hydroxycytidine mutagenesis., PMID:39293594
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial., PMID:39265595
Impact analysis of SARS-CoV-2 vaccination in patients treated with monoclonal antibodies: A monocentric experience., PMID:39265354
Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort., PMID:39247344
Antiviral therapy for COVID-19 virus: A narrative review and bibliometric analysis., PMID:39244809
Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?, PMID:39137507
Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities., PMID:39126484
In Vitro and In Vivo Neutralizing Efficacy of Monoclonal Antibodies Against Sars-Cov-2 Variants in Kidney Transplant Recipients., PMID:39081903
Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium., PMID:39081095
Saliva Is a Sensitive and Accessible Sample Both for SARS-CoV-2 Detection and for the Evaluation of Treatment Effectiveness in Follow-Up Studies., PMID:39066203
Sotrovimab in the treatment of coronavirus disease-2019 (COVID-19): a systematic review and meta-analysis of randomized clinical trials., PMID:39031183
The safety of antivirals and neutralising monoclonal antibodies used in prehospital treatment of Covid-19., PMID:39019401
Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records., PMID:39012863
A review on the current approaches and perspectives of Covid-19 treatment., PMID:39007473
For research use only. Not for human or drug use.
